• Net sales grew 4% (cc[1], +10% USD) mainly driven by:
    • Entresto grew to USD 200 million, +126% (cc) driven by increased uptake world wide
    • Cosentyx was USD 580 million, +35% (cc) with strong growth in all indications and expanded access
    • Oncology returned to growth (+6% cc) driven by Promacta/Revolade, Tafinlar + Mekinist, Jakavi and recent launches
  • Core[1] operating income grew 4% (cc, +11% USD) as higher sales helped support growth and launch investments; Core EPS of USD 1.28, …
  • Net sales grew 4% (cc[1], +10% USD) mainly driven by:
    • Entresto grew to USD 200 million, +126% (cc) driven by increased uptake world wide
    • Cosentyx was USD 580 million, +35% (cc) with strong growth in all indications and expanded access
    • Oncology returned to growth (+6% cc) driven by Promacta/Revolade, Tafinlar + Mekinist, Jakavi and recent launches
  • Core[1] operating income grew 4% (cc, +11% USD) as higher sales helped support growth and launch investments; Core EPS of USD 1.28, …
  • Deal includes reSET®, cleared by FDA for treatment of patients with Substance Use Disorder, and reSET-O™, potential treatment pending FDA clearance for patients with Opioid Use Disorder treated with buprenorphine 
  • Combines Sandoz expertise in launching / commercializing treatments with Pear’s expertise in developing prescription digital therapeutics 
  • Sandoz and Novartis continue to embrace emerging digital technologies to enhance R&D and deliver better outcomes for patients

  • Deal includes reSET®, cleared by FDA for treatment of patients with Substance Use Disorder, and reSET-O™, potential treatment pending FDA clearance for patients with Opioid Use Disorder treated with buprenorphine 
  • Combines Sandoz expertise in launching / commercializing treatments with Pear’s expertise in developing prescription digital therapeutics 
  • Sandoz and Novartis continue to embrace emerging digital technologies to enhance R&D and deliver better outcomes for patients

  • Sandoz White Paper outlines importance of digital solutions to specific local healthcare problems, as part of approach to increasing access to healthcare
  • Publication, which coincides with World Health Day 2018, outlines plans for expanded competition to “reimagine access to healthcare”
  • Upcoming HACk will draw strongly on learnings of past year; publication summarizes progress to date on three winning 2017 projects

Holzkirchen, April 7, 2018 – Sandoz today announces its continued commitment to improving …

  • Sandoz White Paper outlines importance of digital solutions to specific local healthcare problems, as part of approach to increasing access to healthcare
  • Publication, which coincides with World Health Day 2018, outlines plans for expanded competition to “reimagine access to healthcare”
  • Upcoming HACk will draw strongly on learnings of past year; publication summarizes progress to date on three winning 2017 projects

Holzkirchen, April 7, 2018 – Sandoz today announces its continued commitment to improving …

  • Sandoz is seeking approval of biosimilar infliximab for use in all indications of its reference medicine across gastroenterology, rheumatology and dermatology
  • Positive opinion is based on comprehensive clinical and non-clinical data that is expected to confirm that Sandoz biosimilar infliximab matches the reference medicine
  • This recommendation marks the third CHMP positive opinion granted for a Sandoz biosimilar in 12 months following Erelzi® and Rixathon®; Sandoz is on track to launch several biosimilars of major oncology …
  • Sandoz is seeking approval of biosimilar infliximab for use in all indications of its reference medicine across gastroenterology, rheumatology and dermatology
  • Positive opinion is based on comprehensive clinical and non-clinical data that is expected to confirm that Sandoz biosimilar infliximab matches the reference medicine
  • This recommendation marks the third CHMP positive opinion granted for a Sandoz biosimilar in 12 months following Erelzi® and Rixathon®; Sandoz is on track to launch several biosimilars of major oncology …
  • Glatopa® 40 mg/mL is a fully substitutable, AP-rated generic version of Copaxone®* (glatiramer acetate injection) 40 mg/mL
  • Glatopa 40 mg/mL, along with Glatopa® 20 mg/mL, which was launched in the US in June 2015, will offer patients a complete range of dosing options
  • A full range of patient support services for Glatopa® is available through GlatopaCare®

Holzkirchen, February 13, 2018 – Sandoz, a Novartis division, today announced the US FDA approval …

  • Sandoz has been officially certified by the Top Employers Institute for its exceptional employee offerings in Europe and Russia
  • The annual, international research undertaken by the Top Employers Institute recognizes leading employers around the world
  • This exclusive certification underlines Sandoz´ commitment to attract and retain the best people from the industry

Holzkirchen, February 1, 2018 – Sandoz, a Novartis division, is proud to announce that it has officially been certified “TOP Employer Europe 2018” for …